Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
NCT00032747
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
338
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Heart Failure
Interventions
DRUG:
Vasopressin V2 Receptor Antagonist
Sponsor
Sanofi